Cervical cancer can and should be prevented.

TruScreen provides an accurate, real-time screening solution. Our primary screening solution is ideal for communities that cannot access conventional, laboratory dependant, screening methods. It is affordable and easy to learn.

Our purpose is to ensure that all women of screening age, no matter who or where they are, have access to quality screening.

What is TruScreen?

Investing in cervical cancer screening and treatment is highly impactful for several reasons:

  1. High Burden: Cervical cancer is one of the most common cancers among women, especially in low to middle-income countries where screening rates are low.
  2. Preventable: With effective screening and early detection, cervical cancer is highly preventable. Technologies like TruScreen can significantly reduce incidence and mortality rates.
  3. Cost-Effective: Early detection and treatment are far less expensive than treating advanced cancer, making it a cost-effective investment for healthcare systems.
  4. Social Impact: Improving women’s health has a ripple effect on families and communities, enhancing overall societal well-being.
  5. Market Potential: There’s a growing demand for innovative, accessible, and affordable healthcare solutions in emerging markets.

Browse published data

The smart investment

10 years

Established in 2013, TruScreen has been working towards its vision of A World Without Cervical Cancer.

Our People

1 billion +

Our market potential is huge with over a billion women eligible for screening in our key markets.

TruScreen's Markets

600,000+

WHO estimates that in 2020, there was 600,000+ new cases of cervical cancer worldwide.

Learn more about Cervical Cancer

40,000+

The TruScreen device has been clinically validated on over 40,000 women in multiple settings.*

MORE DATA